Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Synlogic Inc (NQ: SYBX )

2.840 +0.030 (+1.07%)
Streaming Delayed Price Updated: 10:37 AM EDT, Oct 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Synlogic Inc

< Previous 1 2 Next >
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Reverse Stock Split
From Synlogic, Inc.
Via GlobeNewswire
Synlogic to Participate in Chardan’s Genetic Medicines Conference
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update
Recent milestones include initiation of the pivotal Phase 3 trial, Synpheny-3, and receipt of Fast Track designation for labafenogene marselecobac as a potential treatment for PKU 
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces International Nonproprietary Name Selection for SYNB1934
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
From Synlogic, Inc.
Via GlobeNewswire
Synlogic to Present at the Jefferies Global Healthcare Conference
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
Presentations included full data from both the Phase 2 Synpheny-1 Study in phenylketonuria and Phase 1 Study for SYNB1353 as a potential treatment for homocystinuria 
From Synlogic, Inc.
Via GlobeNewswire
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Synlogic, Inc.
Via GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for March 9th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Participation in Upcoming Investor and Industry Conferences
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)
From Synlogic, Inc.
Via GlobeNewswire
Sidoti's January Micro-Cap Conference
Via ACCESSWIRE
Synlogic Provides Corporate Update and Outlook for 2023
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update
From Synlogic, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.